We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Levels of NfL Increase Accuracy of Stroke Risk Prediction

By LabMedica International staff writers
Posted on 08 Jul 2019
Serum levels of neurofilament light polypeptide have been found to predict the likelihood of suffering a stroke and to add considerably to the discriminatory power of the Framingham Stroke Risk Score in a group of middle-aged and older adults with diabetes mellitus.

Neurofilament light polypeptide (NfL), also known as neurofilament light chain, is a neurofilament protein that in humans is encoded by the NEFL gene. More...
Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and blood serum and plasma that reflects axonal damage in a wide variety of neurological disorders. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and more recently Huntington's disease.

As effective stroke prevention depends on accurate stroke risk prediction, investigators at the University of Michigan (Ann Arbor, USA) examined the discriminative ability of NfL levels for distinguishing between adults with diabetes mellitus who developed incident stroke and those who remained stroke free during a seven-year follow-up period.

The investigators performed a case-control study of participants selected from the previously completed ACCORD trial (Action to Control Cardiovascular Risk in Diabetes). The 113 cases were all ACCORD subjects who were stroke free at enrollment and developed incident stroke during follow-up. A group of 250 control subjects comprised randomly selected ACCORD subjects who had no stroke events either before or after randomization. NfL levels were measured in baseline samples using Quanterix (Billerica, MA, USA) Single Molecule Array technology.

Results revealed that subjects who developed a stroke had blood levels of NfL that were about 43% higher than those who did not develop a stroke. In contrast, those with the highest NfL levels were 10 times more likely to develop a stroke during the seven-year follow-up period, than those with low levels of NfL.

In addition, the results showed that older age, nonwhite race, higher systolic blood pressure, glomerular filtration rate less than 60, and higher hemoglobin A1C were independent predictors of serum NfL in this cohort, but that diastolic blood pressure, durations of hypertension or diabetes mellitus, and lipid levels were not.

First author Dr. Frederick Korley, assistant professor of emergency medicine at the University of Michigan, said, "The Framingham Stroke Risk Score looks at stroke risk factors in a patient and predicts 10-year probability of a stroke occurring. The score currently includes factors such as diabetes, current smoking status, and blood pressure. When we added NfL levels as a risk factor, the score appeared to become even more accurate in predicting stroke."

The NfL study was published in the July 1, 2019, issue of the journal Stroke.

Related Links:
University of Michigan
Quanterix


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.